Literature DB >> 21139073

Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats.

Yasushi Kirino1, Youichi Sato, Takayuki Kamimoto, Kazuyoshi Kawazoe, Kazuo Minakuchi.   

Abstract

Altered dipeptidyl peptidase-4 (DPP4) activity during the progression of late-stage type 2 diabetes was measured in Otsuka Long-Evans Tokushima fatty (OLETF) rats. Compared with OLETF rats subjected to 30% food restriction, food-satiated OLETF rats exhibited spontaneous hyperphagic obesity, insulin resistance, hyperglycemia, hyperinsulinemia, and increased plasma DPP4 activity during the early phase of the experiment (up to ∼30 wk). Subsequently, their plasma DPP4 activity as well as their body weight, body fat, and plasma insulin concentration declined to control levels during the late phase, resulting in excessive polyuria, proteinuria, dyslipidemia, pancreatic islet atrophy, hypoinsulinemia, and diabetes, which changed from insulin-resistant diabetes to hypoinsulinemic diabetes secondary to progressive islet insufficiency, and their fasting blood glucose level remained high. Since plasma DPP4 activity demonstrated significant positive correlations with body weight and the fasting plasma insulin level but not with the fasting blood glucose level during the late stage of diabetes, body fat and fasting plasma insulin levels may be useful factors for predicting the control of plasma DPP4 activity. In contrast, pancreatic DPP4 activity was significantly increased, and the expression of pancreatic insulin was significantly reduced in late-stage diabetic OLETF rats, suggesting that a relationship exists between the activation of pancreatic DPP4 and insulin depletion in pancreatic islet atrophy. In conclusion, it is suggested that plasma DPP4 activity changes in accordance with the progression of hyperinsulinemic obesity and pancreatic islet atrophy. DPP4 activity may play an important role in insulin homeostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21139073     DOI: 10.1152/ajpendo.00319.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  13 in total

Review 1.  Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.

Authors:  Annayya R Aroor; James R Sowers; Guanghong Jia; Vincent G DeMarco
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

2.  Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.

Authors:  Steven K Malin; Hazel Huang; Anny Mulya; Sangeeta R Kashyap; John P Kirwan
Journal:  Peptides       Date:  2013-07-17       Impact factor: 3.750

Review 3.  DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.

Authors:  Chayakrit Krittanawong; Andrew Xanthopoulos; Takeshi Kitai; Natalia Branis; HongJu Zhang; Marrick Kukin
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

4.  Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.

Authors:  Ruben Rodriguez; Jacqueline N Minas; Jose Pablo Vazquez-Medina; Daisuke Nakano; David G Parkes; Akira Nishiyama; Rudy M Ortiz
Journal:  J Endocrinol       Date:  2018-04-11       Impact factor: 4.286

Review 5.  Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.

Authors:  Jixin Zhong; Quan Gong; Aditya Goud; Srividya Srinivasamaharaj; Sanjay Rajagopalan
Journal:  J Diabetes Res       Date:  2015-05-14       Impact factor: 4.011

6.  Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.

Authors:  Jing Wei Li; Yun Dai Chen; Wei Ren Chen; Jing Jing; Jie Liu; Yong Qiang Yang
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

Review 7.  Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease.

Authors:  Jixin Zhong; Sanjay Rajagopalan
Journal:  Front Immunol       Date:  2015-09-25       Impact factor: 7.561

8.  Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.

Authors:  Yu-Na Chae; Tae-Hyoung Kim; Mi-Kyung Kim; Chang-Yell Shin; Il-Hoon Jung; Yong Sung Sohn; Moon-Ho Son
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

9.  Suppression of pancreatic beta cell apoptosis by Danzhi Jiangtang capsule contributes to the attenuation of type 1 diabetes in rats.

Authors:  Shuguo Zheng; Mengqiu Zhao; Yuanjie Wu; Zheng Wang; Younan Ren
Journal:  BMC Complement Altern Med       Date:  2016-01-27       Impact factor: 3.659

10.  Effect of the low- versus high-intensity exercise training on endoplasmic reticulum stress and GLP-1 in adolescents with type 2 diabetes mellitus.

Authors:  Sung Soo Lee; Jae Ho Yoo; Yong Seok So
Journal:  J Phys Ther Sci       Date:  2015-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.